Main Newsletter
Mastery Series
Therapy Series
 
Bookmark and Share | Print Article | Items for the Week Previous | All Articles This Week | Next
This article originally posted and appeared in  Type 2 DiabetesGenetics of DiabetesIssue 729

Circulating MicroRNAs Associated with Type 2 Diabetes

Researchers identified increases in three miRNAs and decreases in seven miRNAs in patients with type 2 diabetes…. 

Advertisement

Francisco J. Ortega, Ph.D., and colleagues from the Institut d'Investagacio Biomedica de Girona in Spain studied circulating miRNA in 12 men, six of whom had normal glucose tolerance and the other six who had type 2 diabetes. The association of 10 circulating miRNAs with type 2 diabetes was also verified cross-sectionally in another sample of 45 men with normal glucose tolerance and 48 men with type 2 diabetes. A longitudinal validation was carried out in 35 patients with type 2 diabetes in a randomized, three month long metformin trial. Furthermore, circulating miRNAs were studied in seven healthy participants before and after a six hour hyperinsulinemic-euglycemic clamp and insulin plus intralipid/heparin infusion.

Researchers identified increases in three miRNAs and decreases in seven miRNAs in patients with type 2 diabetes. They found that miR-140-5p and miR-423-5p independently accounted for 49.5% of fasting glucose variance after controlling for confounders. These two specific miRNAs along with miR-195 and miR-126 were specific for type 2 diabetes with 89.2% accuracy. Significant reduction in fasting glucose, glycated hemoglobin, and changes in circulating miR-192, miR-140-5p, and miR-22 were seen with metformin but not placebo. Reduction in miR-222 was seen with insulin infusion during clamp, while increases in circulating miR-222 and miR-140-5p were seen with the intralipid/heparin mixture. These results show that there is a close association between circulating miRNAs and type 2 diabetes.

Practice Pearls:
  • Levels of circulating miRNAs vary with insulin action
  • There is an association between circulating miRNAs and type 2 diabetes as they may play a potentially important role in insulin sensitivity

"Circulating MicroRNAs Linked to Type 2 Diabetes."  http://www.ncbi.nlm.nih.gov/pubmed/24478399

Advertisement


 

Bookmark and Share | Print | Category | Home

This article originally posted 16 May, 2014 and appeared in  Type 2 DiabetesGenetics of DiabetesIssue 729

Past five issues: Issue 760 | Diabetes Clinical Mastery Series Issue 219 | SGLT-2 Inhibitors Special Edition December 2014 | Issue 759 | Diabetes Clinical Mastery Series Issue 218 |

2014 Most Popular Articles:

New Guidelines for Doctors to Treat Diabetes
Posted December 12, 2014
Handbook of Diabetes, 4th Ed., Excerpt #20: Foot Problems in Diabetes
Posted November 29, 2014
Why Are Up to 20% Type 2's Nonresponsive to Exercise?
Posted December 05, 2014
Is Type 2 Diabetes an Inflammatory Disease?
Posted November 21, 2014
Carbs Associated with Higher Diabetes and Heart Disease Risk Factor
Posted December 05, 2014
Handbook of Diabetes, 4th Ed., Excerpt #19: Macrovascular Disease in Diabetes
Posted November 23, 2014
Any Pain Medication Said Effective When Treating Diabetic Nerve Pain
Posted November 21, 2014
Knowledge of Onset, Peak, and Duration of Action of Meds Prevents a Trip to the ER
Posted November 24, 2014
Link between Free Fatty Acids and Acute MI, Type 2 Diabetes
Posted November 21, 2014
New Approach Targets Type 2's Poorly Controlled With Metformin
Posted November 14, 2014


Browse by Feature Writer & Article Category.
A. Lee Dellon, MD | Aaron I. Vinik, MD, PhD, FCP, MACP | Beverly Price | Charles W Martin, DD | Derek Lowe, PhD | Dr. Brian Jakes, Jr. | Dr. Fred Pescatore | Dr. Tom Burke, Ph.D | Eric S. Freedland | Evan D. Rosen | Ginger Kanzer-Lewis | Greg Milliger | Kristina Sandstedt | Laura Plunkett | Leonard Lipson, M.A. | Louis H. Philipson | Maria Emanuel Ryan, DDS, PhD | Marilyn Porter, RD, CDE | Melissa Diane Smith | Michael R. Cohen, RPh, MS, ScD, FASHP | Paul Chous, M.A., OD | Philip A. Wood PhD | R. Keith Campbell, Professor, B.Pharm, MBA, CDE | Richard K. Bernstein, MD | Sheri R. Colberg PhD | Sherri Shafer | Stanley Schwartz, MD, FACP, FACE | Steve Pohlit | Steven V. Edelman, M.D. | Timothy S. Hollingshead |

Cast Your Vote
For your prediabetes patients who can't lower their blood glucose with lifestyle changes, do you prescribe GLP-1s or SGLT-2s?
CME/CE of the Week
Warren Joseph, DPM, FIDSA

Category: Wound Care
Credits: .75



Search Articles On Diabetes In Control